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abstract: Objectives: Ataxia-telangiectasia (A-T) is an autosomal recessive multisystem disorder characterised by 
cerebellar degeneration, telangiectasia, radiation sensitivity, immunodeficiency, oxidative stress and cancer suscept- 
ibility. Epidemiological research has shown that carriers of the heterozygous ataxia-telangiectasia mutated (ATM) 
gene mutation are radiosensitive to ionising irradiation and have a higher risk of cancers, type 2 diabetes and athero- 
sclerosis. However, there is currently no fast and reliable laboratory-based method to detect heterozygous ATM 
carriers for family screening and planning purposes. This study therefore aimed to evaluate the ability of a modified 
G2-assay to identify heterozygous ATM carriers in the families of A-T patients. Methods: This study took place 
at the Tehran University of Medical Sciences, Tehran, Iran, between February and December 2017 and included 16 
A-T patients, their parents (obligate heterozygotes) and 30 healthy controls. All of the subjects underwent indiv-
idual radiosensitivity (IRS) assessment using a modified caffeine-treated G2-assay with G2-checkpoint abrogation. 
Results: The mean IRS of the obligate ATM heterozygotes was significantly higher than the healthy controls 
(55.13% ± 5.84% versus 39.03% ± 6.95%; P <0.001), but significantly lower than the A-T patients (55.13% ± 5.84% versus 
87.39% ± 8.29%; P = 0.001). A receiver operating characteristic (ROC) curve analysis of the G2-assay values indicated 
high sensitivity and specificity, with an area under the ROC curve of 0.97 (95% confidence interval: 0.95–1.00). 
Conclusion: The modified G2-assay demonstrated adequate precision and relatively high sensitivity and specificity 
in detecting heterozygous ATM carriers.
Keywords: Ataxia-Telangiectasia; Chromosome Breakage; Genetic Carrier Screening; Heterozygote; Radiation 
Sensitivity; Sensitivity and Specificity.
بتدهور  يتميز  متنحي  الوجوه  متعدد  ا�شطراب ج�شدي  الدموية هو  ال�شعريات  النا�شئ عن متدد  احلركة  اختالج  الهدف: مر�س  امللخ�ص: 
اأظهرت  ال�رصطان.  حدوث  وقابلية  التاأك�شدي  الإجهاد  املناعة،  نق�س  الإ�شعاع،  ح�شا�شية  الدموية،  ال�شعريات  متدد  املخيخ،  وظائف 
ال�رصطان،  حلدوث  اأعلى  وقابلية  املوؤين  لالإ�شعاع  ح�شا�شية  لديهم  املر�س  لهذا  املتغايرة  اجلينية  الطفرات  حاملي  اأن  الأبحاث 
لأكت�شاف  بها  وموثوق  �رصيعة  خمتربية  طريقة  حاليا  يوجد  ل  ذلك،  ومع  ال�رصايني.  ت�شلب  ومر�س  النوعالثاين  من  ال�شكري  وداء 
قدرة  تقييم  اإىل  الدرا�شة  هذه  تهدف  الأ�رصي.  التخطيط  بغر�س  الأ�رصة  اأفراد  لفح�س  املر�س  لهذا  املتغايرة  اجلينية  الطفرات  حاملي 
احلركة. اختالج  مر�شى  عائالت  يف  املر�س  لهذا  املتغايرة  اجلينية  الطفرات  حاملي  حتديد  على  املعدلة  ج2  تفتي�س  نقاط   اختبار 
من  ا  مري�شً  16 و�شملت   2017 ودي�شمرب  فرباير  بني  اإيران،  طهران،  الطبية،  للعلوم  طهران  جامعة  يف  الدرا�شة  هذه  اأجريت  الطريقة: 
كمجموعة  �شحيحا  �شخ�شا   30 و  اجلربيني(  املر�س  )حاملي  اأمورهم  واأولياء  الدموية،  ال�شعريات  متدد  عن  النا�شئ  احلركة  اختالج 
نقاط  اإلغاء  مع  املعدل  ج2  الكافيني  مقيا�س  اختبار  با�شتخدام  الفردية  لالأفراد  احل�شا�شية  لتقييم  امل�شاركني  جميع  خ�شع  ظابطة. 
اأعلى بكثري  املر�س  لهذا  املتغايرة  اجلينية  الطفرات  املجازية حلاملي  لالأفراد  احل�شا�شية  تقييم  النتائج: كانت متو�شطات  التفتي�س ج2. 
احلركة اختالج  مر�شى  من  بكثري  اأقل  ولكنها   ،)P  >0.001 %39.03؛   ±  6.95% مقابل   55.13%  ±  5.84%( ال�شابطة  املجموعة  من 
اإىل ح�شا�شية عالية  اختبار ج2  لقيم  الت�شغيل املتميز  اأ�شار حتليل منحنى   .)P  = %8.29 ± %87.39؛ 0.001  )%5.84 ± %55.13 مقابل 
وخ�شو�شية، مع وجود منطقة حتت املنحنى تبلغ 0.97 )%95 فا�شل الثقة: 1.00-0.95(. اخلال�صة: اأظهر اختبار ج2 املعدل دقة كافية 
وح�شا�شية عالية ن�شبيا يف الك�شف عن حاملي الطفرات اجلينية املتغايرة لهذا املر�س.
الكلمات املفتاحية: اختالج احلركة النا�شئ عن متدد ال�شعريات الدموية؛ تك�رص الكرومو�شومات؛ فح�س حاملي املر�س؛ الطفرات اجلينية 
املتغايرة؛احل�شا�شية لالأ�شعاع؛ احل�شا�شية و اخل�شو�شية. 
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Ataxia-telangiectasia (a-t) is a rare auto-somal recessive pleiotropic syndrome charact-erised by cerebellar ataxia, oculocutaneous tel- 
angiectasia, chromosomal instability, radiosensitivity, 
variable immunodeficiency, oxidative stress and a high risk 
of malignancy.1,2 Worldwide, only one in 40,000–100,000 
neonates is homozygous for the A-T mutated (ATM) 
gene mutation; however, 0.5–2% of the general population 
are heterozygous carriers.1 Although heterozygous ATM 
carriers are commonly asymptomatic, they have a higher 
sensitivity to ionising radiation (IR) and a higher risk of 
type 2 diabetes mellitus, cardiovascular diseases and 
cancers.2,3 However, the exact mechanism and the resp- 
onsible mutations for this increased susceptibility to 
certain cancers are not yet understood.
The ATM gene codes for a ubiquitous serine/
threonine protein kinase that has been implicated in 
the maintenance of genomic stability.1 Over 480 different 
mutations—which occur across the full-length transcript 
without any hotspots—have been described in A-T 
patients.3 In addition, the ATM gene has many polymor- 
phisms/missense DNA changes that must be disting- 
uished from deleterious mutations.1 Early identification 
of the syndrome is useful for establishing prognosis and 
initiating genetic counselling for the family members of 
affected patients.4 However, the diagnosis can be problem- 
atic and is usually based on clinical symptoms as well 
as high levels of serum α-fetoprotein (AFP), acquired 
translocations between chromosomes 7 and 14 in the 
blood karyotype and reduced cell sensitivity to IR or 
the absence of the ATM protein.5 
Despite advancement in functional and sequencing- 
based assays, no reliable low-cost test is yet available for 
identifying A-T patients and heterozygous ATM carriers.6 
However, certain techniques developed to evaluate radio- 
sensitivity in A-T patients may constitute methods of 
differentiating heterozygous ATM carriers, such as G2 
chromosomal radiosensitivity assays, comet assays, fluor- 
escence in situ hybridisation, messenger ribonucleic acid 
(RNA)/microRNA expression profiling of the ATM gene 
and gamma-H2AX and PSMC1 gene assays.6–16 However, 
these findings need to be confirmed among additional 
individuals carrying different ATM gene mutations.
The G2-checkpoint eases chromosome damage 
repair, probably by inhibiting the deleterious progression 
of cells through the cell cycle.17 Caffeine has been reported 
to increase radiosensitivity and abrogate radiation-
induced cell cycle inhibition/delays by inhibiting the 
G2/M checkpoint, either with or without inactivating 
the ATM and A-T Rad3-related genes.18 Terzoudi et al. 
reported that caffeine treatment increased G2-assay 
sensitivity and reduced interlaboratory and intra-experi- 
mental variations.19 Similarly, Pantelias et al. proposed 
a standardised caffeine-treated G2-assay for predicting 
individual radiosensitivity (IRS).20 This study aimed to 
evaluate the ability of a modified caffeine-treated G2 
breakage assay to identify heterozygous ATM carriers 
in the families of A-T patients.
Methods
This study was conducted at the Tehran University 
of Medical Sciences, Tehran, Iran, from February to 
December 2017. A total of 78 individuals were included 
in the study, comprising 16 A-T patients, their 32 parents 
(obligate heterozygotes) and 30 healthy controls. The 
A-T patients were recruited from previously diagnosed 
cases or from those who were being followed-up at the 
Children’s Medical Center Hospital in Tehran. In all cases, 
the A-T diagnosis was based on evidence of disabling 
mutations on both alleles of the ATM gene and either 
increased radiation-induced chromosomal breakage in 
cultured cells or progressive cerebellar ataxia.5 Addit-
ional supportive tests, including specific serum AFP and 
immunoglobulin measurements, were also carried out. 
The control subjects were recruited from members of 
staff at the Children’s Medical Center Hospital and the 
Department of Medical Genetics, Tehran University of 
Medical Sciences. Only individuals who were unrelated 
to A-T patients and had no family history of malignancy, 
atherosclerosis or type 2 diabetes were included as 
controls. The controls were approximately matched 
for age and gender with the heterozygous ATM carriers.
A total of 2 mL of peripheral blood was collected 
from each subject. A modified G2 breakage assay was 
performed based on previously published protocols.20 
Briefly, 1 mL of whole blood was added to 10 mL of 
Gibco™ Roswell Park Memorial Institute 1640 medium 
(Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) and supplemented with 15% fetal bovine serum, 
2% phytohaemagglutinin, 1% L-glutamine and 1% penic- 
Advances in Knowledge 
- This study demonstrates the relatively high sensitivity and specificity of a modified caffeine-treated G2-assay in the detection of 
heterozygous carriers of the ataxia-telangiectasia mutated (ATM) gene mutation.
Application to Patient Care
- A modified caffeine-treated G2-assay is proposed as an alternative method for identifying heterozygous ATM carriers within the 
families of patients with ataxia-telangiectasia for family screening and planning purposes.
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Figure 1: Diagrams showing chromatid breaks and gaps (arrows) in a peripheral blood lymphocyte at metaphase stage 
from a heterozygous carrier of the ataxia-telangiectasia mutated gene mutation after 0.9 Grays per minute of gamma 
irradiation using (A) conventional and (B) modified G2-assays.
Figure 2: Box plot of the individual radiosensitivity percentages of healthy controls, heterozygous ataxia-telangiectasia 
(A-T) mutated gene carriers and A-T patients after 0.9 Grays per minute of gamma irradiation (N = 78).
IRS = individual radiosensitivity; ATM = ataxia-telangiectasia (A-T) mutated.
Table 1: Demographic and clinical data of ataxia-telangiectasia patients (N = 16)


























1 Yes 14/M 5 6 103 960 0 195 40
2 Yes 9/M 2 3 161 670 7 225 7
3 Yes 7/M 1 1 380 809 173 111 10
4 Yes 4/F 2 3 90 982 16 100 1
5 Yes 16/F 1 2 75 <5 4 284 14
6 No 11/M 2 5 406 1,200 145 200 NA
7 No 11/F 2 8 104 5 1 208 <1
8 No 9/M 1 5 150 613 <5 60 <1
9 Yes 10/F 7 9 319 687 595 149 5
10 No 4/M 1 1 30 468 7 89 <1
11 No 10/F 2 4 520 NA NA NA NA
12 Yes 22/M NA NA 666 1,185 249 112 NA
13 Yes 10/M 3 2 619 826 108 43 <1
14 Yes 10/F 1 1 155 <1 <1 430 <1
15 Yes 7/F 2 7 87 143 9 2,257 <1
16 Yes 8/F 1 8 157 643 1 71 <1
AFP = α-fetoprotein; Ig = immunoglobulin; M = male; F = female; NA = not available.
Asghar Aghamohammadi, Seyed M. Akrami, Marjan Yaghmaie, Nima Rezaei, Gholamreza Azizi, Mehdi Yaseri, 
Hassan Nosrati and Majid Zaki-Dizaji
Clinical and Basic Research | e443
illin/streptomycin. The mixture was then incubated for 
72 hours at 37 °C in a humidified incubator with 5% 
carbon dioxide. Each sample was cultured in two flasks 
to assess spontaneous breakage and radiation-induced 
breakage. After 72 hours, gamma irradiation was perf-
ormed using a Theratron® 780E teletherapy machine 
(MDS Nordion Inc., Ottawa, Ontario, Canada) at a dose 
rate of 0.9 Grays (Gy) per minute for 1.12 minutes at 
room temperature. After irradiation, each culture was 
divided into two flasks, of which one was treated with 
4 mM of caffeine, before being incubated for 20 minutes 
at 37 °C. The cultures were then treated with demecolcine 
for 75 minutes. After incubation, the cells were harvested, 
prepared on slides and stained with Giemsa according 
to conventional cytogenetic techniques.21
Stained slides were coded and underwent blinded 
analysis by two separate researchers. Only well-spread 
metaphases with 44–47 chromosomes each were eval- 
uated. For each sample, a total of 50 metaphases were 
examined for chromatid aberrations (i.e. breaks and 
gaps). Moreover, the level of spontaneous chromatid 
anomalies was evaluated in non-irradiated lymphocyte 
cultures and the resultant number was subtracted 
from the radiation-induced G2 yield of chromatid 
breaks. A chromatid gap was defined as an interruption 
in the staining of a chromatid greater than the width 
of the chromatid, without displacement of the segment 
distal to the lesion.22 A lesion was considered to be a 
chromatid break if there was distinct dislocation and 
misalignment of the broken segment [Figure 1].
For each individual, two different yields of chrom- 
atid aberrations were calculated. The first yield was 
similar to that of a conventional G2-assay and the second 
was the maximum yield of chromatid breaks achieved 
when the G2-checkpoint was abolished by caffeine. The 
I R S 
was calculated as below [Equation 1]:
where G2caf is the yield when the G2-checkpoint is 
abolished by caffeine and G2 is the conventional 
G2-assay yield. For samples which deviated by more or 
less than 5% from formerly published cut-off values, 
an additional 50 metaphases were analysed.20 The freq- 
uency of exchanges and rings was not included in the 
calculation of aberration yields. The inter-day precision 
of the G2-assay was determined by analysing six samples 
of peripheral blood mononuclear cells from one healthy 
donor on six different days. The precision of the test was 
assessed only at between-run levels.
Data were analysed using GraphPad Prism software, 
Version 6 (GraphPad Software, San Diego, California, 
USA). Statistical differences between groups were deter- 
mined using Kruskal-Wallis and Dunn’s multiple comp- 
arison post-hoc tests. Receiver operating characteristic 
(ROC) curves were calculated to assess the relevant 
sensitivity and specificity of the G2-assay values. A sign- 
ificance level of P ≤0.050 was used throughout the experi- 
ments. The inter-day precision was presented as a coeff- 
icient of variation.
This study was approved by the Research Ethics 
Committee of the Tehran University of Medical Sciences 
(#26489-154-02-93). All subjects gave informed consent 
prior to their inclusion in the study.
Results 
The male-to-female ratios of the A-T patients and controls 
were 0.9 and 1.4, respectively. The mean ages of the A-T 
patients, heterozygous ATM carriers and healthy controls 
were 10, 37 and 32 years old, respectively (ranges: 4–22, 
26–55 and 19–46 years, respectively). The clinical and 
demographic data of the A-T patients are presented 
in Table 1. 
There was a significant increase in IRS across all 
three groups (P <0.001). The mean frequency of induced 
chromatid aberrations in cells from heterozygous ATM 
carriers were significantly higher than in those from 
healthy controls (55.13% ± 5.84% versus 39.03% ± 
6.95%; P <0.001) and significantly lower than in A-T 
patients (55.13% ± 5.84% versus 87.39% ± 8.29%; 
P = 0.001) [Figure 2]. An ROC curve analysis of 
G2-assay values demonstrated high sensitivity and 
specificity for the identification of heterozygous ATM 
Figure 3: Receiver operating characteristic curve analysis of G2-assay data for (A) healthy controls versus heterozygous 
ataxia-telangiectasia mutated (ATM) gene carriers, (B) healthy controls versus ataxia-telangiectasia (A-T) patients and (C) 
heterozygous ATM carriers versus A-T patients (N = 78). 
(1 [Equation 1]IRS = × 100)- G2G2 G2-caf caf
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carriers versus controls, with an area under the curve of 
0.97 (95% confidence interval: 0.95–1.00) [Figure 3 and 
Table 2]. The overall inter-day coefficient of variation 
of the assay was 4.28% (mean: 45.84% ± 1.96%).
Overall, the G2-checkpoint efficiency was easily 
discriminated in A-T patients; however, there was an 
overlap of chromatid aberration frequencies observed 
between controls and heterozygous ATM carriers. 
Aberrations in non-irradiated lymphocytes were not 
noticeable in any of the three groups.
Discussion 
Along with chromosomal instability, cells with ATM 
gene mutations display extreme radiosensitivity both 
in vivo and in vitro.3 These phenotypes suggest that 
the ATM gene plays a critical role in the DNA repair 
system. Furthermore, as serine/threonine kinase acts 
as a sensor of oxidative stress in normal cells, the loss of 
this protein in individuals with ATM mutations disturbs 
the redox balance and increases levels of reactive 
oxygen species and oxidative stress, contributing to 
increased radiosensitivity.23,24 However, the exact role 
of the ATM gene in these systems and the tissue spec-
ificity of such defects remains unknown. The ATM gene 
coordinates cell cycle checkpoint signalling via the 
phosphorylation of different substrates, including p53, 
checkpoint kinase 2, structural maintenance of chromo- 
somes 1 (SMC1), activating transcription factor 2 and 
nibrin.1 A lack of serine/threonine kinase leads to the 
loss of these checkpoints and, therefore, the potentially 
deleterious progression of cells through the cell cycle. 
The screening and identification of heterozygous 
carriers of ATM-related haploinsufficiencies and allelic 
variants is an important public health goal due to their 
high frequency in the population and increased suscept- 
ibility to cancer, diabetes and atherosclerosis.1,2 The 
current study evaluated the IRS of A-T patients, hetero- 
zygous ATM carriers and healthy controls by assessing the 
frequency of radiation-induced chromatid aberrations 
during the G2/M transition stage in stimulated blood 
lymphocytes using a modified caffeine-treated G2-assay 
with G2-checkpoint abrogation. A significantly higher 
frequency of chromatid breaks and gaps was observed 
in the cells of A-T patients compared to those of the 
heterozygous ATM carriers. Similarly, there was a 
significantly higher frequency of chromatid breaks and 
gaps among the cells of heterozygous ATM carriers 
compared to those of the healthy controls. Unfortunately, 
the range of these aberrations overlapped to some extent 
between the latter two groups, thus precluding the 
absolute detection of heterozygous ATM carriers. Never- 
theless, this method—which required only 2 mL of 
peripheral blood from the subjects—showed acceptable 
inter-day variation and relatively high sensitivity and 
specificity for the identification of heterozygous ATM 
carriers.
Several previous studies have attempted to dist- 
inguish heterozygous ATM carriers from normal controls 
using G2-assays.7,8,25 Tchirkov et al. detected 13 hetero- 
zygous ATM carriers without any overlap of results 
with those of normal donors.10 However, these findings 
were not consistent with those of other studies.22,26–28 
This may be due to variations in the number of subjects, 
type of cells under consideration, nature of the ATM 
mutation, technical procedures, treatment dose and 
dose rate, number of analysed metaphases, time interval 
between irradiation and fixation and the type of 
analysed aberration. Leonard et al. distinguished 
obligate heterozygotes from controls utilising lympho- 
blast cell lines which had been treated with campto-
thecin; however, this method requires further study 
using peripheral blood samples from a larger cohort.11 
Likewise, Terzoudi et al. introduced a new approach to 
G2/M cell cycle checkpoint abrogation for assessing IRS 
using caffeine treatment; this method demonstrated 
better discrimination and minimal intra-individual and 
inter-laboratory variations compared to the conventional 
G2-assay.19,20
Claes et al. reported the use of a modified S-G2 
micronucleus assay in which caffeine treatment formed 
a complementary assay for the identification of atypical 
A-T patients and heterozygous ATM carriers.29 Prodosmo 
et al. proposed a new, fast and cost-effective test to deter- 
mine ATM zygosity based on p53 centrosomal local- 
isation visualised by immunofluorescence staining.30 
Porcedda et al. identified heterozygotes using a two-
tier analysis of histone H2AX phosphorylation, H2AX 
phosphorylation levels and residual gamma-H2AX 
Table 2: Diagnostic potential of a modified G2-assay in 
the differentiation of healthy controls, heterozygous ataxia- 
telangiectasia mutated gene carriers and ataxia-telangi-











































A-T = ataxia-telangiectasia; ATM = A-T mutated; AUC = area under 
the curve; CI = confidence interval.
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foci.16 In addition, A-T patients and heterozygous ATM 
carriers have been identified by evaluating serine/threo- 
nine kinase-dependent phosphorylation of SMC1 foll- 
owing DNA damage; however, this assay could not 
discriminate between carriers and controls via enzyme- 
linked immunosorbent assay.31 A more recent, quick, 
labour-intensive cell division assay using flow cytometry 
reported similar results to that of a colony-survival 
assay (CSA).32 A CSA is the gold-standard method of 
evaluating radiosensitivity as it resolves the technical 
difficulties involved in standardisation and optimisation 
which interfere with predictive accuracy.5 
This study was subject to certain limitations. Some 
of the healthy controls may have been DNA repair-
deficient or radiosensitive.20,22 On the other hand, some 
of the obligate heterozygotes may have had a range 
of ATM mutations; consequently, these individuals 
may, like A-T patients, have exhibited various degrees 
of radiosensitivity both in vitro and clinically.7–11,19,25,28,29 
Furthermore, technical issues in different laboratories 
can intensify such variations.22 Finally, the assay was 
not specific for ATM mutations and may therefore 
have identified mutations in other genes which modify 
DNA repair system efficiency. For these reasons, it is 
recommended that this assay be used only for the 
screening of families of confirmed A-T patients, 
as hypersensitivity in such cases is more likely to 
truly reflect heterozygosity of the ATM gene.33,34 
Further investigation is recommended to confirm 
the practicality of using this assay. The results of 
experiments like those conducted in the current study 
are preliminary and need to be further confirmed in 
additional subjects carrying different ATM mutations.
Conclusion
The results of this study indicate that a modified caffeine 
treated G2-assay is a potential method of identifying 
heterozygous ATM carriers within the families of A-T 
patients. 
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